Ligand Pharmaceuticals Inc.

LGNDNASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
300.14 USD
↘ 2.43 (0.80%)AT CLOSE (11:59 AM EDT)
296.99
↘ 3.15 (1.05%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
296.99
↘ 3.15 (1.05%)
🔴Market: CLOSED

Shares of Ligand Pharmaceuticals Inc. (LGND) are trading at $300.89. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, LGND is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Aug 6, 2026.

Open?$306.08
High?$317.49
Low?$297.31
Prev. Close?$302.57
Volume?393.8K
Avg. Volume?397.7K
VWAP?$307.63
Rel. Volume?0.99x
Bid / Ask
Bid?$123.05 × 200
Ask?$492.17 × 200
Spread?$369.12
Midpoint?$307.61
Valuation & Ratios
Market Cap?6.0B
Shares Out?20.0M
Float?18.9M
Float %?94.2%
P/E Ratio?39.17
P/B Ratio?6.03
EPS?$7.66
Dividend?0.00%
Ex-Dividend?N/A
RelatedANIPADMA
News
Profile
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Themes
Biotech - Drug Development›Clinical-Stage Platforms
Employees
47
Market Cap
6.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.ligand.com
Listed
1994-11-25
Address
3911 SORRENTO VALLEY BLVD
SAN DIEGO, CA 92121
Phone: 858-550-7500
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
57
Short Sent.?
65
Piotroski F-Score?4/9Mixed
Altman Z-Score?8.38Safe
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.16%High
Short Interest?1.9M
Days to Cover?5.0
Free Float18.9M
Avg Daily Volume384.6K
Settlement Date2026-07-15
Financial Health
Current Ratio?21.28Strong
Quick Ratio?20.95Strong
Cash Ratio?2.83Strong
Debt/Equity?0.45Low
ValuationRICHLY VALUEDvs 2 peers + S&P 500
Score
39/100
P/E?
Peers
33
S&P
18
39.2PRICEY▾
P/B?
Peers
33
S&P
30
6.03FAIR▾
P/S?
Peers
33
S&P
3
21.91HIGH▾
P/FCF?
Peers
33
S&P
10
48.9PRICEY▾
EV/EBITDA?
Peers
33
S&P
3
47.2HIGH▾
EV/Sales?
Peers
33
S&P
3
23.12HIGH▾
Returns & Efficiency
ROE?
Peers
67
S&P
55
15.4%STRONG▾
ROA?
Peers
67
S&P
74
10.0%STRONG▾
Cash Flow & Enterprise
FCF?$123.0M
Enterprise Value?$6.3B
Fundamentals ratios updated end of day
MarketsMoversWatchlist